That’s a key question. How do we translate these results from a randomized controlled clinical trial into clinical practice? So, I think we have to separate things. There are things that can be done on a population-based level, which is, of course, everything we would like. Meaning that all of the population can be at risk for dementia and we would like all the population to benefit from this kind of program but we also know that it’s unrealistic to implement such detail and training in the whole population...
That’s a key question. How do we translate these results from a randomized controlled clinical trial into clinical practice? So, I think we have to separate things. There are things that can be done on a population-based level, which is, of course, everything we would like. Meaning that all of the population can be at risk for dementia and we would like all the population to benefit from this kind of program but we also know that it’s unrealistic to implement such detail and training in the whole population. So, we need to have several levels of prevention, with a first level, which would be the population-based level, where that can be implemented through a general practitioner, through politics and through public health policy across the world. Which could be very basic advice or monitoring of certain factors in the general population and then in more at-risk individuals that could be identified in brain health services, meaning memory clinics. So, people will come here, they have concerns regarding their memory, we identify their risk, like if they have for example markers of amyloidopathy or tauopathy or neurodegeneration or lifestyle factors that we can identify and then propose them targeted approaches to reduce their risk of dementia. So, it could be a two-level approach, general population and then brain health services for individuals with a specific concern who may be more at risk with specific risk and specific intervention. And when I mean also specific intervention, I mean, beyond the lifestyle intervention I mentioned, with currently ongoing randomized controlled clinical trials using drugs like anti-amyloid antibodies in asymptomatic individuals or anti-tau vaccine or everything that could be tested in these at-risk populations.
